StandoutStocks.com: "Stocks that Standout" picks for today are: ACCP, SMWF, SUWN, TSTA, UNDT

Dec 17, 2008 (M2 PRESSWIRE via COMTEX) -- UNDT | Quote | Chart | News | PowerRating -- StandoutStocks.com "Stocks that Standout" picks for today are: Access Pharmaceuticals, INC. (OTCBB: ACCP), Seamless Corporation (OTCBB: SMWF), Sunwin International Neutraceuticals, Inc. (OTCBB: SUWN), TurboSonic Technologies, Inc. (OTCBB: TSTA), Universal Detection Technology (OTCBB: UNDT)...and Proudly Introducing Proprietary Push Technology (PPT).

The Newest and Revolutionary Technology for Increasing Investor Visability.

REAL Awareness for REAL Companies.

Click below for a full demonstration.

http://newmediaadvisors.info/newmedia.swf

Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at www.Standoutstocks.com

Dec 17, 2008 -- Access Pharmaceuticals, INC. (OTCBB: ACCP | Quote | Chart | News | PowerRating) and MACROCHEM CORPORATION (OTCBB: MACM) announced today that the results of two Phase 3 studies of pexiganan for the topical treatment of mild diabetic foot infection were published in the December 15, 2008 issue of Clinical Infectious Diseases. The publication was authored by Benjamin A. Lipsky, M.D., Veteran's Affairs Puget Sound Healthcare System and the University of Washington School of Medicine, Seattle, WA; Kenneth J. Holroyd, M.D., Vanderbilt University School of Medicine, Nashville, TN; and Michael Zasloff, M.D., Georgetown University School of Medicine, Washington, D.C. The authors concluded that based on the data from these Phase 3 studies, topical pexiganan might be an effective alternative to oral antibiotic therapy in treating diabetic patients with a mildly infected foot ulcer, and might reduce the risk of selecting antimicrobial-resistant bacteria.

Overall, 835 patients were randomized; those in each treatment arm were similar with regard to dermographic and clinical characteristics. Although study 303 failed to demonstrate equivalence, study 304 and the combined data for the 2 trials demonstrated equivalent results (within the 95% confidence interval) for topical pexiganan and oral ofloxacin in clinical improvement rates (85%-90%), overall microbiological eradication rates (42%-47%), and wound healing rates. The incidence of worsening cellulitis (2%-4%) and amputation (2%-3%) did not differ significantly between treatment arms. Bacterial resistance to ofloxacin emerged in some patients who received ofloxacin, but no significant resistance to pexiganan emerged among patients who received pexiganan.

"We believe pexiganan will become a valuable treatment alternative for patients with mildly infected foot ulcers and we support continuation of clinical development to further demonstrate pexiganan's efficacy and safety as a treatment option in this patient population," stated Jeffrey B. Davis, Access' Chief Executive Officer. "We are actively seeking a partner with dermatology expertise to assist in the development and ultimate commercialization of this important treatment option."

On July 10, 2008, Access Pharmaceuticals, Inc. (OTC BB: ACCP.OB) announced it had signed an agreement and plan of merger with MacroChem pursuant to which MacroChem is expected to be merged with and into a wholly-owned subsidiary of Access. The transaction is expected to close in early 2009.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate.

About MacroChem:

MacroChem is expected to be merged with and into a wholly-owned subsidiary of Access in early 2009. MacroChem is a specialty pharmaceutical company that develops and seeks to commercialize pharmaceutical products. Product candidates in our clinical development portfolio are: pexiganan, EcoNail(R) and SR9025 which was recently acquired. Pexiganan, a novel topical anti-infective for the treatment of diabetic foot infection, was recently in-licensed and has already completed two Phase 3 trials. EcoNail is a topically applied SEPA-based econazole lacquer for the treatment of onychomycosis, a condition commonly known as nail fungus. SR9025 is a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers.

On April 23, 2008, MacroChem announced it acquired Virium Pharmaceuticals Inc. Virium was a nonpublic, development stage company whose business is developing and commercializing novel therapeutics with a focus in oncology. By acquiring Virium, the Company has in-licensed a group of product candidates targeted for development and commercialization in several oncology or oncology related indications. These opportunities involve compounds that Virium believes show promising late stage, pre-clinical or early clinical data.

Dec 17, 2008 -- Seamless Corporation (OTCBB: SMWF | Quote | Chart | News | PowerRating) announced today that on December 18, 2008, Dr. Gadget will appear on the Tyra Banks Show presenting the SNBK-1, Seamless's Mini Net Book Computer. The December 18th show is Tyra's annual holiday show.

The SNBK-1 provides full power computing in an ultra mobile package that weighs only 1.2 kilos. Incorporating a 1.6Ghz processor, 10.2" TVT LCD with 1024 by 600 resolution, 120 gigabyte hard drive, Wi-Fi, camera and speakers, the SNBK-1 is a price-competitive laptop for mobile users that need a high-performance lightweight computer. MSRP is just under $499.

Seamless also announced on Tuesday that the SNBK-1 Mini Net Book is now available through Ingram Micro Inc., the world's largest technology distributor. This vendor relationship agreement will enable the Seamless SNBK-1 to be accessible to Ingram Micro's vast network of reseller customers in the United States, including many of the channel's largest players.

More information and technical specifications for the SNBK-1 Mini Net Book are available at www.snotebk.com.

"Dr. Gadget's appearance with the SNK-1 on the Tyra Banks holiday show is an exceptional opportunity for Seamless," stated Ken Reda, Manager of Seamless Sales LLC.

About Dr. Gadget

Dr. Gadget, AKA Dave Dettman is the world's #1 consumer product promoter while being recognized as a nationally known television and radio personality. A published author, inventor, marketing expert and consumer product specialist in the field of product development, Mr. Dettman features the latest and greatest consumer products that come to the marketplace. Dr. Gadget can be regularly seen on the ABC's The View, nationally syndicated television show EXTRA and many more TV and Radio shows.

About The Tyra Banks Show

The Tyra Banks Show is a Daytime Emmy Award-winning American talk show hosted by supermodel and America's Next Top Model creator Tyra Banks. It is recorded in front of a live-to-tape audience at Chelsea Studios in New York City. The show covers a variety of topics, focusing on current issues facing women, with often special episodes on America's Next Top Model. The show is aired in many countries, and is also available on XM Satellite Radio's Take Five channel in both the United States and Canada. On June 20, 2008, The Tyra Banks Show won a Daytime Emmy in the "Outstanding Talk Show Informative" category.

About Seamless

Seamless Corporation is quoted on the OTCBB: SMWF. Seamless develops and markets secure cutting-edge hardware and software Internet communications products and services through its three operating subsidiaries: Seamless TEK Ware Inc. develops hardware products such as the S-Gen, Mini notebooks and MP3/4 players, Seamless TEK LABS, Inc. develops secure internet software such as S-SIB and Phenom for secure internet conferencing, and Seamless Sales LLC sells both subsidiaries products.

Dec 17, 2008 -- Sunwin International Neutraceuticals, Inc. (OTCBB: SUWN), a leader in the production and distribution of Chinese herbs, veterinary medicines and one of the world's leading producers of all natural, zero calorie Stevia in China, today announced its second quarter results for fiscal 2009 for the quarter ended October 31, 2008.

The quarter showed continued growth in revenue and a significant rise in net income even as the company increased general and administrative expenses ahead of further global sales growth. Recent developments in the US market where Stevia is pending FDA approval as a sweetener ingredient include an announcement by Coca Cola to launch in the US an all natural low calorie beverage using Stevia and comments by Pepsi Co. of products launched in markets outside the US. Sunwin is positioned to become the largest independent Stevia provider able to supply across the US market for table top, wholesale and bulk sale needs.

Financial Highlights:

Revenues for the second quarter of fiscal 2009 increased 15.4% to $6.56 million as compared to revenues of $5.68 million in the second quarter of fiscal 2008. Net income in the second quarter of fiscal 2009 was approximately $421,000, a 135% increase compared to approximately $179,000 in the second quarter of fiscal 2008.

For the first half of fiscal 2009, revenue increased 29.2% to $12.79 million and net income increased 47.5% to more than $715,000. Gross margins remain steady at approximately 25% reflecting variances and offsets in costs related to the global economic upheavals affecting the cost of raw materials, energy and shipping. The company was able to control costs in order to maintain its current margins.

The significant increase in quarter over quarter net income was primarily attributable to ongoing revenue growth, cost controls and efficiency gains within the business, less increased general and administrative expenses associated with the company's organic and strategic growth. Selling expenses declined year over year. Income from operations net of these changes increased 192% on a quarter to quarter comparison. Sunwin also became a tax payer in China reducing the current year quarterly net income by $92,430 compared to no income taxes paid in the prior year quarter. First half net income was reduced by $166,600 in taxes year to date compared to the prior year period of zero taxes paid.

The fiscal second quarter is the major purchasing period for Stevia raw leaf stock by the Company and as a result, inventories increased through raw materials purchases from $4.7 million at fiscal 2008 year end to $9.2 million at the end of the second quarter ahead of expected demand. While inventories increased substantially, cash and cash equivalents as of October 31, 2008 were $6.78 million, down only slightly from $6.81 million at fiscal 2008 year end. This demonstrates the company's increasing ability to generate internal working capital to fund its growth programs as it addresses the increasing worldwide demand for Stevia products.

President and Chairman Laiwang Zhang, commented, "Sunwin posted yet another strong quarter of growth, profit and conservative fiscal management of the company's assets. The company made significant inventory purchases to increase stevia production to meet expected growth in global demand, eventually to include expected high US market demand as product manufacturers are openly discussing their plans to launch low calorie products using Stevia upon FDA approval. Sunwin is uniquely positioned to address this potential demand as a vertically integrated supplier able to provide both intermediate grades needed by other producers to create high grade Stevia, as well as produce and deliver high grade Stevia customized to a customer's particular needs at competitive costs. In the interim, Sunwin continues to grow its business outside the US in current and recently approved markets to the benefit of the bottom line for our shareholders."

Outlook:

Sunwin expects to continue its growth in international markets where the bulk of Stevia sales are today through increased production at its present facilities and broader distribution of product through wholesale channels, as well as the provision of mid-grade Stevia to other manufacturers who face limited supply scenarios of this product critical for the production of high-grade Stevia.

The company anticipates its acquisition of a 60% interest in Qufu Shengwang Stevia Biology and Science Company will add revenue and profit in the quarters ahead by expanding the business base in agricultural products and profitably monetizing Stevia waste products generated from the production of Stevia.

Sunwin's proprietary OnlySweet(TM) brand of dietary supplements sold in retail stores across the US continues to grow with increasing interest from major chain retailers and online distributors. OnlySweet unit sales increased 34% during the second quarter of 2009 as compared to the prior year. Expected US approval of Stevia is expected to open further distribution and sales of the tabletop product currently sold, as well as significantly increase wholesale and bulk opportunities for the food and beverage industry in which Sunwin currently participates. Sunwin's customer Zevia was recently featured as one of the fastest growing companies in its category, which we believe is a strong indication of the US market potential for Stevia and Sunwin.

Jeff Reynolds, President of the company's US subsidiary, commented, "The company continues to see needs for increasing production of both mid-grade and high-grade Stevia to meet growing global demand, and anticipates demand increasing upon US FDA approval of Stevia. We believe that US approval will also open significant interest in launching new products, which will increase Stevia demand, as well as create additional demand on currently limited industry production capacity for high-grade Stevia. Sunwin is uniquely positioned as a vertically integrated producer and seller to meet the need for high quality Stevia at competitive prices."

About Sunwin International Neutraceuticals, Inc.

Sunwin International Neutraceuticals, Inc. engages in the areas of essential traditional Chinese medicine, zero calorie natural sweeteners (stevia), and veterinary medicines and feeds prepared from 100 percent organic herbal ingredients. As an industry leader in agricultural processing, Sunwin has built an integrated global firm with the sourcing and production capabilities to meet the needs of consumers throughout the world. Sunwin also makes such value-added products as specialty veterinary food ingredients and specialty feed ingredients.

Dec 17, 2008 -- TurboSonic Technologies, Inc. (OTCBB: TSTA), a global leader in the design and supply of industrial air pollution control technologies, today announced receipt of a US$1 million contract to supply a SonicKleen(TM) Wet Electrostatic Precipitator (WESP) system for emissions control for a US biofuel producer. A WESP is the best available emissions control technology for collection of fine respirable particulate, condensable matter, and acid mist; respirable particulate has been identified as a preventable health risk. We anticipate that the equipment associated with this contract will be delivered to the customer in the current fiscal year.

Edward Spink, TurboSonic's CEO commented, "Another order from our longest-standing customer in the biofuels industry! We have experienced increasing interest in our SonicKleen(TM) WESP systems from biofuel producers, with three equipment supply contracts in-house for that industry alone. TurboSonic is recognized as a leader in air pollution control systems, with its proprietary designs known for advanced features and reliability. We believe that the momentum of "green" energy will continue to provide us with significant opportunities moving forward, especially as the international energy industry endeavors to meet the demand for renewable fuels, necessary to reduce carbon emissions."

About TurboSonic Technologies, Inc.

TurboSonic Technologies designs and markets air pollution control technologies to industrial customers worldwide. Its products help companies in the Cement and Mineral Processing, Ethanol, Metals & Mining, Petrochemicals, Power Generation, Pulp & Paper, Waste Incineration, and Wood Products industries meet the strictest emissions regulations, improve performance and reduce operating costs.

Dec 16, 2008 -- Universal Detection Technology (OTCBB: UNDT | Quote | Chart | News | PowerRating) (FRANKFURT: PO8), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats and provider of counter-terrorism consulting and training services, reported today that it has received a purchase order for its anthrax detection equipment from the city of Calgary, Canada Police Service. The purchase order comes from the department's terrorism training division. The detection equipment is designed to check for anthrax and can return results in as little as 3 minutes.

The Calgary Police Service, located in Calgary, Alberta, Canada, is made up of more than 1,600 police officers and 855 civilian members. Calgary is the largest city in the province of Alberta, Canada. The metropolitan population was 1,162,310 in 2006.

A report released last week by the Commission on the Prevention of Weapons of Mass Destruction Proliferation and Terrorism says urgent security measures need to be taken soon or the world is likely to undergo an incident of terrorism using weapons of mass destruction within the next five years. "Unless the world community acts decisively and with great urgency, it is more likely than not that a weapon of mass destruction will be used in a terrorist attack somewhere in the world by the end of 2013," the report states in the opening sentence of the executive summary. The report also emphasizes the need of the new administration to prepare the nation against a future bioterrorist attack.

TO WATCH A VIDEO OF THE REPORT PLEASE GO TO: http://cosmos.bcst.yahoo.com/up/player/popup/index.php?cl=10944062.

UNDT's anthrax detection equipment has been extensively used by first responders and private industry throughout the country. The equipment has been evaluated by the U.S. DOD as well as the United Kingdom military. The equipment's capacities include:

-- No cross-reactivity with near neighbor strains -- No cross-reactivity to household powders -- No set up time -- No expensive reader needed -- No decontamination requirements -- No false positives -- No false negatives -- No hook effect

"This is our first purchase order from Canada as we expand marketing our products internationally," said Mr. Jacques Tizabi, UNDT's Chief Executive Officer.

UNDT has received the purchase orders referred to in this news release through Security Solutions International (SSI). The equipment was billed to the City of Calgary Police Service by SSI as part of participation in the counter-terrorism training at the Gulf Coast Terrorism Conference and has been delivered to them directly from UDT.

About Universal Detection Technology

Universal Detection Technology is a developer of monitoring technologies, including bioterrorism detection devices. The Company on its own and with development partners is positioned to capitalize on opportunities related to Homeland Security. For example, the Company, in cooperation with NASA, has developed a bacterial spore detector that detects certain biohazard substances. The Company is also a reseller of handheld assays used for detection of five bioterrorism agents, radiation detection systems, and antimicrobial products.

About Standoutstocks.com

Standoutstocks.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies. Standoutstocks.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at www.Standoutstocks.com and select the "join now" button.

Join us at www.standoutstocks.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. Standoutstocks.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Standoutstocks.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Standoutstocks.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Standoutstocks.com is owned and operated by Standoutstocks.com. Neither Standoutstocks.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Standoutstocks.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Standoutstocks.com statements and opinions and such statements and opinions cannot be considered independent. Standoutstocks.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Standoutstocks.com services are often paid for using free-trading shares. Standoutstocks.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: www.standoutstocks.com/disclaimer.aspx

CONTACT: Standoutstocks.com e-mail: info@standoutstocks.com WWW: http://www.standoutstocks.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index